← Eichor
Study identifier: NCT06832267 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL

Condition: Primary Central Nervous System Lymphoma  ·  Sponsor: Zhejiang Cancer Hospital

PhaseNA
Planned participants44
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This study aims to observe and explore the efficacy and safety of Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) regimen as first-line therapy for primary central nervous system diffuse large B-cell lymphomas(PCNS DLBCL)

This description comes directly from the study's public registry record.

Talk to the study team

Haiyan Yang, PhD  ·  0571-88122192  ·  yanghy@zjcc.org.cn

Haifeng Yu, MD  ·  15157155533  ·  yuhaifeng5533@dingtalk.com

Always discuss trial participation with your own doctor first.

Locations (1)

Zhejiang Cancer HospitalHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06832267